LEXINGTON, Mass.--(BUSINESS WIRE)--
Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the
Company will present a poster at the 30th Annual North American Cystic
Fibrosis Conference being held October 27-29, 2016, in Orlando, Florida.
Data describing the relative bioavailability of CTP-656 under fasted and
fed conditions along with results from the Phase 1 multiple ascending
dose study will be presented. Details on the upcoming poster
presentation follow below.
Title: CTP-656 Multiple Dose Pharmacokinetic Profile Continues to
Support a Once-Daily Potentiator for Cystic Fibrosis Patients with
Poster Session I: Thursday, October 27, 11:15 a.m.-1:45 p.m.
Poster Number: 224
About CTP-656 and Cystic Fibrosis
CTP-656 is a novel CFTR potentiator that may offer next generation,
once-daily dosing and was developed by Concert's application of its
novel deuterium chemistry to modify ivacaftor. Concert is initially
developing CTP-656 as a potential monotherapy treatment for cystic
fibrosis due to gating mutations of the gene that encodes for cystic
fibrosis transmembrane conductance regulator (CFTR), a protein, which
regulates components of sweat, mucus clearance and digestion. Cystic
fibrosis is a life-threatening, hereditary genetic disease that has
systemic effects and can cause significantly reduced lung and digestive
system function. According to the Cystic Fibrosis Foundation, an
estimated 70,000 people worldwide have cystic fibrosis.
Pharmaceuticals is a clinical stage biopharmaceutical company
focused on applying its DCE
Platform® (deuterated chemical entity platform) to create novel
medicines designed to address unmet patient needs. The Company's
approach starts with approved drugs in which deuterium substitution has
the potential to enhance clinical safety, tolerability or efficacy.
Concert has a broad
pipeline of innovative medicines targeting pulmonary diseases,
including cystic fibrosis, central nervous systems (CNS) disorders, as
well as autoimmune and inflammatory diseases. For more information
please visit www.concertpharma.com.
Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and
DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160921006475/en/
Concert Pharmaceuticals, Inc.
Justine E. Koenigsberg, 781-674-5284
Source: Concert Pharmaceuticals, Inc.
News Provided by Acquire Media